Lung adenocarcinoma is still possible to metastasize and spread when taking targeted drugs. Molecular targeted therapy is a new type of anti-tumor method, which uses molecular biological differences between tumor cells and normal cells, adopts methods such as blocking signaling pathway, sealing receptors and inhibiting angiogenesis to act on specific target points of tumor cells, specifically inhibit the proliferation, invasion and metastasis of tumor cells, and prompt their apoptosis. Lung adenocarcinoma patients taking targeted drugs need to take genetic test, ALK positive, can take crizotinib treatment; EGFR mutation, can take gefitinib, erlotinib and other targeted drugs; targeted therapy can relieve clinical symptoms, reduce pain, improve quality of life, prolong the survival period, but can not cure lung cancer, and can not ensure the effectiveness rate of 100%. Taking targeted drugs for a long time may be resistant to drugs, and metastasis and proliferation may occur if the disease is not well controlled; the disease progresses and metastasis and proliferation occur in the process of applying targeted drugs, suggesting that the drugs are ineffective, and it is necessary to have regular review to find out the progress of the disease and to take new therapeutic measures. If you have any symptoms of physical discomfort, you should go to the hospital in time and consult your physician for guidance.